Igenica Biotherapeutics – a biotech star-studded with execs that, in previous career incarnations brought a number of antibody drug conjugate drugs to market – just raised a modest round of funding to further develop its own ADCs.
The Bay Area startup brought in $5 million of a proposed $6.25 million round, according to a regulatory filing. This is its most recent fundraise since the $14 million it brought in a year ago as a Series C add-on. Historically, its investor base includes The Column Group, OrbiMed, 5AM Ventures and Third Rock Ventures.
Igenica is going solidly after the precision medicine space: It says it evaluates patient profile, tissue expression, tumor environment and antibody function to profile proteins found on tumor cell surfaces to identify potential ADC candidates. Its approach is to cast a wide net for potential ADCs to be used as cancer therapeutics, advancing several candidates concurrently at a rapid clip.
Behavioral Health, Interoperability and eConsent: Meeting the Demands of CMS Final Rule Compliance
In a webinar on April 16 at 1pm ET, Aneesh Chopra will moderate a discussion with executives from DocuSign, Velatura, and behavioral health providers on eConsent, health information exchange and compliance with the CMS Final Rule on interoperability.
The company’s lead ADC, called IGN 523, is in Phase 1 trials to test safety in treating acute myelogeneous leukemia. It’s also got programs underway meant to treat lung cancer, pancreatic cancer, other leukemias and solid tumor cancers.
Igenica says IGN-523 works the way many ADCs do: It induces antibody-dependent cell-mediated cytotoxicity, inhibits of the function of a cell surface protein that’s linked to many blood and solid tumor cancers called CD98, and also brings about apoptosis.
